FGF21 may have a potential role as a therapeutic agent for conditions associated with insulin resistance as it has been shown that administration of a recombinant form of this hormone in obese mice and diabetic monkeys improves insulin sensitivity, body weight, and lipid profile (9, 10, 11, 12, 13, 14). The gene discussed is FGF21; the disease is Insulin resistance.